National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Understanding Cancer Series: Estrogen Receptors/SERMs
< Back to Main
    Posted: 01/28/2005    Updated: 04/27/2006    Reviewed: 09/01/2006
Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
View/Print PDF  View/Print PDF
View/Print PowerPoint  View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Slide 16 : Tamoxifen and Breast Cancer Treatment previousnext

In women who have breast cancer, proliferation of the breast cancer cells is often driven by estrogen, just as in the case of normal breast cells.

Since tamoxifen can block the effects of estrogen on breast cells, scientists predicted that breast cancer could be treated by using tamoxifen to interfere with estrogen-induced cell proliferation. Based on encouraging results obtained in experimental trials, tamoxifen was first approved for such use in breast cancer treatment in the 1970s.

The first step in treating women with breast cancer is to surgically remove the cancer from the breast. It is difficult to be certain that every cancer cell has been removed at the time of surgery because some breast cancer cells could have spread to surrounding tissues or other organs prior to the operation. Therefore, women often receive some type of treatment after surgery (adjuvant therapy) to prevent the growth of any cancer cells that might remain in the body. Studies show that when tamoxifen is used for this purpose, the risk of cancer recurrence is reduced.

Tamoxifen and Breast Cancer Treatment

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov